Bausch & Lomb said to be on the block for $10 billion

13 December 2012

Privately-held eyecare specialist Bausch & Lomb has reportedly been put up for sale by private equity company Warburg Pincus with a $10 billion price tag.

A Bloomberg report says that Warburg Pincus, which acquired the business in 2007, has appointed Goldman Sachs to help it find a buyer, although Bausch & Lomb's owner is also said to be considering an initial public offering (IPO) for the business.

The private equity firm acquired the 160-year-old eyecare specialist in 2007 in a $3.7 billion deal, when the company was dealing with falling sales and litigation over injuries caused by one of its eyecare products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK